Skip to content

Meeting · senate

Hearings to examine Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity.

2024-09-24 · 14:00

Source status: Scheduled

Committee

Location

562, Dirksen Senate Office Building

Video

Official published hearing

Congress.gov explicitly associates this publication with this proceeding.

  • S.Hrg.118-473

    WHY IS NOVO NORDISK CHARGING AMERICANS WITH DIABETES AND OBESITY OUTRAGEOUSLY HIGH PRICES FOR OZEMPIC AND WEGOVY

    No. 473 · 2024-09-24 · GovInfo record 2025-05-07

Source: https://api.congress.gov/v3/committee-meeting/118/senate/335960